New web tool helps cancer patients alert relatives about genetic risks

NCT ID NCT05552664

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a web-based program called GIFT that helps cancer patients share information about inherited cancer risks with their relatives. Over 3,000 patients and their family members took part. The goal was to see if the tool encourages more relatives to get genetic testing and talk to their doctors about cancer prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
web-based family communication program
What this could lead to
If successful, this approach could help more families learn about their inherited cancer risks and take steps to prevent or catch cancer early.
What could go wrong
This study is observational and does not test a new treatment. The results may not apply to all families or cancer types, and the impact on actual cancer outcomes is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

3,002 people

The number who actually took part.

Started

Oct 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for the PICS survey are: 1. diagnosed with any cancer at any stage in 2018-2019 and reported to the Georgia or California SEER registries 2. Been found to carry a pathogenic variant (PV) in one of 27 cancer susceptibility genes (see Table 4) according to the Georgia California Genetic Testing Linkage Initiative dataset 3. aged 18 or older 4. alive at the time of selection as determined through linkage with Georgia and California vital statistics data. Additional eligibility criteria for Patient Trial Invitation will be evaluated from patient response to the PICS survey and will include patient report of: 1. Receipt of genetic testing for cancer risk 2. A positive test result (pathogenic variant; PV) Inclusion criteria for Relative Trial Invitation are assessed via patient report: 1. first-degree (biological parent, sibling, or biological child) or second-degree (biological half-sibling, aunt, uncle, nephew, niece, grandparent, or grandchild) relative of a patient enrolled in the study; 2. aged 18 or older; 3. alive at the time of study invitation; 4. relative lives in the United States or Canada (countries in which Color genetic testing is available, most people speak either English or Spanish, and test kit shipping costs are not exorbitant) Additional eligibility criteria for Relative Trial Enrollment will be evaluated from relative response to the relative eligibility screening survey (see Appendix C) and will include: 1. confirmation from the relative that they have not received clinical genetic testing ordered by a doctor or genetic counselor within the past five years (proxy for having already been tested for the PV carried by the patient who invited them into the study); 2. confirmation of age 18 or older; 3. confirmation of first-degree (biological parent, sibling, or biological child) or second-degree (biological half-sibling, aunt, uncle, nephew, niece, grandparent, or grandchild) relation to the patient. 4. confirmation of residence in United States or Canada Exclusion Criteria Exclusion criteria for the PICS survey are: 1\) Age\<18 Additional exclusion criteria for Patient Trial Invitation: 1. Patients who do not report receipt of genetic testing 2. Patients who do not report a positive genetic test result (PV) Exclusion criteria for Relative Trial Invitation are: 1. Age\<18 2. Relative does not live in the United States or Canada Additional exclusion criteria for Relative Trial Enrollment include relative report of: 1. Age\<18; 2. Receipt of genetic testing ordered by a doctor or genetic counselor within the past five years; 3. Relationship to proband (inviting) patient other than first- or second-degree relative 4. Residence in a country other than United States or Canada

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Stanford University

    Stanford, California, 94305, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48108, United States

  • University of Southern California

    Los Angeles, California, 90007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.